^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
amelimumab (SY101)
i
Other names: SY101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Tasly
Drug class:
EGFR inhibitor
Related drugs:
1year
A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies. (PubMed, Ther Adv Med Oncol)
The Ametumumab was well tolerated and safe in patients with advanced solid malignancies, exhibiting minimal immunogenicity, a long half-life, high levels of drug exposure in the blood, and preliminary effectiveness. The trial was registered with CTR20170343 on 10 April 2017, The China Center for Drug Evaluation.
P1 data • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
amelimumab (SY101)
over1year
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer (clinicaltrials.gov)
P2b, N=84, Not yet recruiting, Shanghai Celfuture Biotech Co., Ltd.
New P2b trial • Combination therapy • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
|
KRAS wild-type • NRAS wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • amelimumab (SY101)
Share via
